2nd Circ. OKs $2.7M In Fees From BioScrip Investor Deal

By Adam Lidgett (May 23, 2019, 6:10 PM EDT) -- The Second Circuit on Thursday said Bernstein Litowitz Berger & Grossmann LLP could collect $2.7 million in attorney fees from a $10.9 million deal inked between BioScrip Inc. and shareholders who accused the specialty pharmacy of lying about fraud tied to Novartis AG's iron-reducing drug Exjade....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!